Supernus Pharmaceuticals (SUPN) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Does the media refer more to JAZZ or SUPN?

In the previous week, Jazz Pharmaceuticals had 15 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 3 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.09 beat Supernus Pharmaceuticals' score of 0.76 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	10 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation and earnings, JAZZ or SUPN?

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.07B	1.63	$560.12M	$7.50	14.59
Supernus Pharmaceuticals	$661.82M	2.71	$73.86M	$1.11	28.82

Is JAZZ or SUPN more profitable?

Jazz Pharmaceuticals has a net margin of 11.86% compared to Supernus Pharmaceuticals' net margin of 9.27%. Jazz Pharmaceuticals' return on equity of 26.62% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.86%	26.62%	9.14%
Supernus Pharmaceuticals	9.27%	12.23%	9.17%

Do institutionals & insiders believe in JAZZ or SUPN?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has more risk & volatility, JAZZ or SUPN?

Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Do analysts rate JAZZ or SUPN?

Jazz Pharmaceuticals presently has a consensus target price of $184.00, indicating a potential upside of 68.12%. Supernus Pharmaceuticals has a consensus target price of $36.00, indicating a potential upside of 12.52%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92
Supernus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.